KIF5B-RET fusions in lung adenocarcinoma
Nature Medicine2012Vol. 18(3), pp. 375–377
Citations Over TimeTop 1% of 2012 papers
Takashi Kohno, Hitoshi Ichikawa, Yasushi Totoki, Kazuki Yasuda, Masaki Hiramoto, Takao Nammo, Hiromi Sakamoto, Koji Tsuta, Koh Furuta, Yoko Shimada, Reika Iwakawa, Hideaki Ogiwara, Takahiro Oike, Masato Enari, Aaron J. Schetter, Hirokazu Okayama, Aage Haugen, Vidar Skaug, Suenori Chiku, Itaru Yamanaka, Yasuhito Arai, Shun‐ichi Watanabe, Ikuo Sekine, Seishi Ogawa, Curtis C. Harris, Hitoshi Tsuda, Teruhiko Yoshida, Jun Yokota, Tatsuhiro Shibata
Related Papers
- → Targeting RET Receptor Tyrosine Kinase Activation in Cancer(2010)148 cited
- → Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers(2017)105 cited
- → Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2(2020)11 cited
- → Activity of novel RET inhibitors against RET genotypes associated with medullary thyroid cancer.(2010)3 cited
- → Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by Reverse Phase Protein Array.(2013)